SMMT SMMT
Company Profile ↓Company Overview
SMMT (SMMT) is a publicly traded company listed on with a market capitalization of $10.49B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -50.02% |
| 6 Months: | -7.27% |
| 3 Months: | -22.86% |
| 1 Month: | -14.80% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 53.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 148.00K | 324.00K | 170.00K | 181.00K | 192.00K | 57.00K | 1.31M | 250.00K | 235.00K | 220.00K | 0 | 0 | 0 | - | - | 0 | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 568.44M | 234.21M | 224.88M | 195.21M | 220.50M |
| Operating Income | -6.19M | -9.34M | -15.36M | -16.94M | -16.92M | -23.73M | -19.49M | -22.16M | -12.69M | -16.94M | -537.15M | -15.79M | -20.49M | -42.39M | -59.62M | -58.38M | - | - | -568.44M | -234.21M | -224.88M | -195.21M | -220.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -568.40M | -231.75M | -219.08M | -195.17M | -220.45M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.00K | 0 | 0 | 0 | 0 | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -565.71M | -231.79M | -219.12M | -189.42M | -215.70M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.38M | -6.13M | -15.28M | -17.74M | -17.49M | -24.42M | -19.60M | -21.40M | -16.77M | -21.39M | -542.38M | -14.72M | -21.27M | -43.47M | -60.38M | -56.25M | - | - | -565.71M | -231.79M | -219.17M | -189.42M | -215.70M |
| Diluted EPS | -0.20 | -0.09 | -0.23 | -0.26 | -0.21 | -0.27 | -0.20 | -0.15 | -0.12 | -0.10 | -1.43 | -0.02 | -0.03 | -0.06 | -0.09 | -0.08 | - | - | -0.76 | -0.31 | -0.29 | -0.24 | -0.28 |
| R&D Expense | 9.95M | 12.91M | 13.57M | 13.73M | 18.38M | 23.92M | 19.94M | 20.56M | 9.01M | 17.05M | 9.88M | 9.45M | 15.32M | 30.87M | - | - | - | 51.27M | 208.02M | - | - | 132.62M | 157.73M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 57.09M | 743.00K | 860.00K | - | 705.00K | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 64.33M | 88.73M | 210.98M | 1.09B |
| Operating Income | 5.39M | -27.47M | -53.19M | - | -63.62M | -88.73M | -210.98M | -1.09B |
| EBITDA | - | - | - | - | -73.12M | -598.27M | -212.53M | -1.08B |
| Interest Expense | - | - | - | - | 4.40M | 16.46M | 8.69M | 0 |
| Pretax Income | - | - | - | - | -78.78M | -614.93M | -221.30M | -1.08B |
| Tax Provision | - | - | - | 0 | - | - | - | - |
| Net Income | 10.87M | -29.13M | -52.70M | - | -78.78M | -614.93M | -221.31M | -1.08B |
| Diluted EPS | 0.63 | -0.89 | -0.76 | - | -0.41 | -0.99 | -0.31 | -1.44 |
| R&D Expense | 52.00M | 39.81M | 53.27M | 85.35M | 52.00M | 59.47M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 96.25M | 102.50M | - | 664.17M | 202.95M | 435.56M | 751.18M |
| Current Assets | - | - | - | - | - | 656.71M | 189.71M | 423.75M | 720.30M |
| Cash & Equivalents | - | - | 63.84M | 66.42M | - | 348.61M | 71.42M | 104.86M | 225.27M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 1.46M | 349.00K | 0 | - | - |
| Total Liabilities | - | - | 17.39M | 23.05M | - | 537.51M | 125.26M | 46.81M | 92.32M |
| Current Liabilities | - | - | 13.77M | 19.89M | - | 38.78M | 20.41M | 41.73M | 72.99M |
| Long Term Debt | - | - | - | - | - | 494.54M | 100.00M | - | - |
| Total Debt | - | - | - | - | - | 518.76M | 106.10M | 7.22M | 20.89M |
| Total Equity | -3.59M | 57.59M | 78.86M | 79.45M | - | 126.65M | 77.69M | 388.75M | 658.86M |
| Shares Outstanding | - | - | - | - | - | 211.09M | 701.66M | 737.63M | 775.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -35.11M | -20.76M | -48.11M | - | -41.58M | -76.76M | -142.11M | -322.93M |
| Investing Cash Flow | -331.00K | -341.00K | -421.00K | - | -624.00K | -587.77M | -205.34M | -174.31M |
| Financing Cash Flow | 44.51M | 49.51M | 50.55M | - | 620.24M | 86.51M | 381.23M | 617.53M |
| Capital Expenditure | -157.00K | -205.00K | -421.00K | - | -624.00K | -128.00K | -139.00K | -657.00K |
| Free Cash Flow | -35.26M | -20.96M | -48.53M | - | -42.21M | -76.89M | -142.25M | -323.59M |
| Net Change in Cash | - | - | - | - | 578.04M | -578.02M | 33.78M | 120.29M |
| Dividends Paid | 0 | 0 | 0 | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | 9.4% | -3,697.6% | -6,185.2% | - | -9,024.3% | - | - | - |
| Net Margin % | 19.0% | -3,920.2% | -6,127.6% | - | -11,174.8% | - | - | - |
| ROE % | 18.9% | -36.9% | -66.3% | - | -62.2% | -791.5% | -56.9% | -163.9% |
| ROCE % | - | -33.3% | -64.4% | - | -10.2% | -48.6% | -53.6% | -161.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SMMT
Why Is SMMT Stock Tumbling Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQTlhuRnNfVWRVOWZCX0g1TFhOLUVaMHJmVmhHRjlrYXpnSnk1a1ZSS3djdTExZGpILWdDdjdSMi1GclBUclZvRmlmSHhEZDB6Y3hzUnl5amE0NXZXQkdqQWZPQTM2cWxmN3NEVnkwQlJKaXhsbFhpRmp4YWl1Zkp2eFQ2aEtGYWhZRE1vXz…
Summit Therapeutics (SMMT) Stock Looks Stretched On Fresh Lung Cancer Data - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPUGtQcUlkX2NxVm9NOXAwUC1iMlJCUGF0UU9oN0l2RkUyZDdSU1lJVVN5UVRFdFpyZkVHdW5hYjFCYVFYZE5YWVhGa2ZmTk1rLVFudC1fcHFyXzVnR3lkT1FJaGo4a25udXE5NnlRcTJIdkV1NTRpRDA4b2t5TTRCdHByU21zUER6VGIzST…
Summit’s Global Bladder Cancer Trial Aims to Enroll About 800 Patients - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOQVBMT3VNYVNIc0owLXFWODJiNDVMMlV2OWVrR1Izbk12MkxTRXgyRWZ0X3J4YmpYY051WlVlSUtIMm5LeHIxQTRqcko2cnBSUzkteC1ITDRZWHZHc3pXLV9BaTUtTEkzS2RxdWlKb1NfZU1PRC0waWowa0tWSHZ5R2VycXZWY3l6Q0pJWj…
Summit Therapeutics (SMMT) Could Be 52% Undervalued Following New Ivonescimab Trial Updates - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxONUVHamxpUnZ5TWxhZlpoTmV1U1BNV2V1ck8zYzVNUU0wbFBLR1ZpMWZDdkpTNUtZY2RKWHpFUE1Qblp6bTRZVGExZjJHZUdJWVltb3JkTzA1UzFBazlCT3NHOVVQWmU0TWExOEFKbUZxbkpNX19yeUg3MnN0d0FLUXc3SUZJemVGTkZwWT…
$SMMT stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQQ1pxbFF2bkNyMEYwNk51N1V6WHBzM21WVUN1UkxDS3ZqYzI5OURhNkFvM1VzNXFSV01aemVoNG9peXQzcURaLWVPVkpTTW9fMWh0SVV5VzhEb3NsQmZqVnhtb1VCQjhHVmFWdGtzcm44N1c4MjFIOFloUkQ0amNZc0pVTkZiYU9LTS1zZD…
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches (SMMT) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSTRMVEh1ZVhUWXQwQ1pWVV8xRnJhZ18zTXA3ZjBIV0dSSS1BUm5BQlFvSjlpaEc1OUJsS2NCbDBxeXVGaGZpZXFpRlJDODI4dnhIUjRtbTRMdWFsWFhXRl80eXRWcXQxekxUeWo4SUhXeEwxdVJMT1FSQnNYTzAtRHBaTUNkMzMxbG9XVm…
SMMT — Frequently Asked Questions
What is the current share price of SMMT?
As of 2026-08-05 17:25 PDT, SMMT trades at $13.53 on NASDAQ/NYSE. Its 52-week range is $12.55 to $29.32.
What is the market capitalisation of SMMT?
SMMT has a market capitalisation of $10.49B on NASDAQ/NYSE.
What is the P/E ratio of SMMT?
SMMT trades at a trailing price-to-earnings (P/E) ratio of -9.40. Its price-to-book (P/B) ratio is 15.92.
Is SMMT a good stock to buy?
This page provides a data-driven analysis of SMMT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.